Dronedarone (Multaq▼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg twice daily.
Dronederone was only approved by NICE as a second line drug in August 2010. Use of dronedarone may be associated with:
- an elevated risk of worsening, or new-onset, heart failure
- liver toxicity
Patients should be asked to be vigilant for the symptoms of heart failure or liver toxicity during treatment, and should undergo regular liver-function testing.
More advise for healthcare professional can be found here.